Shijiazhuang Pharmaceutical To Focus On Biopharmaceuticals
This article was originally published in PharmAsia News
Shijiazhuang Pharmaceutical Group and Unigene Laboratories have started operating their joint venture firm Unigene Biotechnology. Using Unigene Laboratories technology, the new company will produce and sell recombinant calcitonin products. It will also integrate Shijiazhuang's liposome technology and nanobiotechnology to fully develop its core competitiveness. The two partners will invest in biopharmaceutical manufacturing facilities compliant with the current U.S. GMP guidelines, as well as set up a biopharmaceutical laboratory. Shijiazhuang plans to invest 3.54 billion yuan ($516 million) on biopharmaceutical fixed asset to commercialize its pharmaceutical preparations globally. When completed, it expects total revenue to reach 11 billion yuan ($1.6 billion) a year with normal production. (Click here for more - Chinese Language)
You may also be interested in...
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.